Skip to content

Ceftazidime/avibactam versus polymyxin B in the treatment of infections due to extensively drug-resistant Gram-negative bacteria

Ceftazidime/avibactam versus polymyxin B in the treatment of infections due to extensively drug-resistant Gram-negative bacteria

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078790
Enrollment
Unknown
Registered
2023-12-19
Start date
2023-12-21
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infections due to extensively drug-resistant Gram-negative bacteria

Interventions

Polymyxin B group:None
Combined group:None

Sponsors

Shandong Provincial Hospital Affiliated to Shandong First Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) patients with the documented extensively drug-resistant Gram-negative bacteria (XDR-GNB) infections including Pseudomonas aeruginosa and Enterobacteriaceae; (2) patients received intravenous ceftazidime/avibactam or intravenous polymyxin B as the initial treatment for more than 2 days; (3) age=18 years.

Exclusion criteria

Exclusion criteria: (1) pregnancy or lactation; (2) incomplete clinical data

Design outcomes

Primary

MeasureTime frame
all-cause mortality at 28 day;

Secondary

MeasureTime frame
all-cause mortality at 14 day;proportion of patients with bacterial eradication at 14 day;proportion of patients with clinical response at 14 day;Iincidence of acute kidney injury;hospital length of stay;days of antibiotics-free within 28 days;days of mechanical ventilation within 28 days;days of renal replacement therapy within 28 days;days with vasopressors within 28days;

Countries

China

Contacts

Public ContactJuan Zeng

Shandong Provincial Hospital Affiliated to Shandong First Medical University

nine2652@163.com+86 151 6886 7561

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026